Author's response to reviews

Title: Breast density in women with familial risk for breast cancer as indicator for the use of mammography or MRI to screen for breast cancer (FaMRIsc): a multicentre randomized controlled trial

Authors:

Sepideh Sepideh Saadatmand (S.Saadatmand@erasmusmc.nl)
Emiel JT Rutgers (e.rutgers@nki.nl)
Rob AEM Tollenaar (r.a.e.m.tollenaar@lumc.nl)
Hermien M Zonderland (h.m.zonderland@amc.uva.nl)
Margreet GEM Ausems (m.g.e.m.ausems@umcutrecht.nl)
Kristien BMI Keymeulen (k.keymeulen@mumc.nl)
Margreet S Schlooz-Vries (m.schlooz-vries@chir.umcn.nl)
Linetta B Koppert (l.koppert@erasmusmc.nl)
Eveline AM Heijnsdijk (e.heijnsdijk@erasmusmc.nl)
Caroline Seynaeve (c.seynaeve@erasmusmc.nl)
Cees Verhoef (c.verhoef@erasmusmc.nl)
Jan C Oosterwijk (j.c.oosterwijk@umcg.nl)
Inge-Marie Obdeijn (a.obdeijn@erasmusmc.nl)
Harry J de Koning (h.dekoning@erasmusmc.nl)
Madeleine MA Tilanus-Linthorst (m.tilanus-linthorst@erasmusmc.nl)

Version: 2 Date: 16 August 2012

Author's response to reviews: see over
Dear Dr. de Jesus,

Thank you for your very quick email regarding our study protocol “Breast density in women with familial risk for breast cancer as indicator for the use of mammography or MRI to screen for breast cancer (FaMRIsc): a multicentre randomized controlled trial”.

We understand that peer reviewing of the study protocol is not necessary since it has received several major funds and is already approved by the Institutional Review Board of the Erasmus University Medical Centre (reference-number: MEC-2010-292).

We have emailed you prove of the ethical approval and the external funding including details of the amount of funding awarded for the study, as asked under point 1 of your email.

Comment 2 stated; “Ethical Approval - Research involving human subjects (including human material or human data) that is reported in the manuscript must have been performed with the approval of an appropriate ethics committee. Research carried out on humans must be in compliance with the Helsinki Declaration (http://www.wma.net/en/30publications/10policies/b3/index.html). A statement to this effect must appear in the Methods section of the manuscript, including the name of the body which gave approval, with a reference number where appropriate.”

We have added this statement including appropriate reference-number on page 7, in the Methods, line 2 under subheading Trial design.

Thank you again for your email.

Sincerely,

Sepideh Saadatmand Madeleine Tilanus-Linthorst